155 related articles for article (PubMed ID: 1329621)
21. In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.
Rudrik JT; Ferrigno SR; Gee SL
Diagn Microbiol Infect Dis; 1991; 14(4):355-60. PubMed ID: 1889186
[TBL] [Abstract][Full Text] [Related]
22. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
Tanaka M; Hoshino K; Ishida H; Sato K; Hayakawa I; Osada Y
Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
[TBL] [Abstract][Full Text] [Related]
24. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
[TBL] [Abstract][Full Text] [Related]
25. SYN987, SYN1193, and SYN1253, new quinolones highly active against gram-positive cocci.
Kitzis MD; Goldstein FW; Ishida N; Acar JF
J Antimicrob Chemother; 1995 Jul; 36(1):209-13. PubMed ID: 8537267
[TBL] [Abstract][Full Text] [Related]
26. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
[TBL] [Abstract][Full Text] [Related]
28. In vitro antibacterial activity of Q-35, a new fluoroquinolone.
Ito T; Otsuki M; Nishino T
Antimicrob Agents Chemother; 1992 Aug; 36(8):1708-14. PubMed ID: 1329626
[TBL] [Abstract][Full Text] [Related]
29. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R
J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
[TBL] [Abstract][Full Text] [Related]
30. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Lauderdale TL; Shiau YR; Lai JF; Chen HC; King CH
Antimicrob Agents Chemother; 2010 Mar; 54(3):1338-42. PubMed ID: 20065058
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone.
Visser MR; Rozenberg-Arska M; Beumer H; Hoepelman IM; Verhoef J
Antimicrob Agents Chemother; 1991 May; 35(5):858-68. PubMed ID: 1854167
[TBL] [Abstract][Full Text] [Related]
32. Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.
Qadri SM; Ueno Y; Postle G; Tullo D; San Pedro J
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):372-7. PubMed ID: 8394816
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G
Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525
[TBL] [Abstract][Full Text] [Related]
34. In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Wickman PA; Black JA; Moland ES; Thomson KS
Antimicrob Agents Chemother; 2006 Jun; 50(6):2255-7. PubMed ID: 16723599
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.
Bassetti M; Dembry LM; Farrel PA; Callan DA; Andriole VT
Antimicrob Agents Chemother; 2002 Jan; 46(1):234-8. PubMed ID: 11751142
[TBL] [Abstract][Full Text] [Related]
36. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
Okuda J; Okamoto S; Takahata M; Nishino T
Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
[TBL] [Abstract][Full Text] [Related]
38. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
Rolston KV; LeBlanc B; Gooch G; Ho DH; Bodey GP
J Antimicrob Chemother; 1989 Mar; 23(3):363-71. PubMed ID: 2732120
[TBL] [Abstract][Full Text] [Related]
39. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.
Lawrence T; Rotstein C; Beam TR; Gorzynski EA; Amsterdam D
Antimicrob Agents Chemother; 1993 Apr; 37(4):896-900. PubMed ID: 8494388
[TBL] [Abstract][Full Text] [Related]
40. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
